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Abstract: Foraminifera carbonate exoskeleton was hydrothermally converted to 
biocompatible and biodegradable zinc-tricalcium phosphate (Zn-TCP) as an alternative 
biomimetic material for bone fracture repair. Zn-TCP samples implanted in a rat tibial 
defect model for eight weeks were compared with unfilled defect and beta-tricalcium 
phosphate showing accelerated bone regeneration compared with the control groups, with 
statistically significant bone mineral density and bone mineral content growth. CT images 
of the defect showed restoration of cancellous bone in Zn-TCP and only minimal growth in 
control group. Histological slices reveal bone in-growth within the pores and porous 
chamber of the material detailing good bone-material integration with the presence of 
blood vessels. These results exhibit the future potential of biomimetic Zn-TCP as bone 
grafts for bone fracture repair.  
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1. Introduction 
Throughout time, bone fracture has continued to impact societies, increasing socioeconomic burden 
to patients. While advancement in medical technologies has helped in the recovery process, it is 
expected by society that improvements in treatment are continually made. This has sparked an era of 
development in innovative biomaterial and opened the field of bone tissue engineering, in order to 
address this ongoing trauma. In simple terms, the goal is to develop more biologically active materials 
that can reduce the recovery time thereby reducing the costs and patient discomfort. Currently, there is 
a wide range of materials that are available clinically, and amongst these, calcium phosphate 
bioceramics have been extensively studied and developed as bone grafts. While these byproducts can 
“do the job”, the bone repair process is a complex system with many factors contributing to its growth. 
This has led biomaterial scientists to take on a biomimetic approach, looking towards nature for 
alternative materials. With all the discoveries in the vast ocean, the marine world has barely been 
uncovered, and many prospective and potentially beneficial materials have yet to be discovered. In our 
previous studies, foraminifera calcareous exoskeleton was identified to possess uniformly and 
interconnected pores capable of stimulating key bone remodeling cells [1] once hydrothermally 
converted to calcium phosphate. Furthermore, the material was shown to also be an effective drug 
delivery carrier for bone stimulating drugs [2–5]. Hydrothermal conversion, first developed in  
1974 [6], allows the carbonate within the material to be substituted with phosphate ions thereby 
making it more biocompatible and biodegradable [7,8]. It should be noted that the integrity of the 
original structure is preserved during this process. In this study, we investigated first, the ability to 
synthetically modify the chemical composition of the material to include zinc ions to produce zinc 
tricalcium phosphate (Zn-TCP) and subsequently evaluating the bone repair properties of Zn-TCP in a 
rat tibial defect model. Key bioinorganic ions such as strontium and magnesium are commonly 
incorporated into biomaterials to be released over time to supplement and stimulate the bone 
regeneration process by acting on or in combination with osteoblast and osteoclast cells. Zinc ions, 
commonly associated with cell regulation, have been shown to affect the processes of physiological bone 
homeostasis and pathological bone turnover [9]. In humans, zinc intake has been positively correlated 
with bone mineral content in premenopausal women [10], whereas zinc deficiency has been linked to 
growth retardation and hypogonadism [11], conditions that affect skeletal maturation and integrity. 
Zinc is a nutritional factor that has long been recognized as important for prenatal and postnatal 
skeletal development, whereas supplementation ameliorates pathological bone loss [9]. Zinc 
differentially regulates bone formation and bone resorption promoting an osteoblastic gene program 
while repressing osteoclast differentiation [12–14] leading to a stimulatory effect on bone formation 
and mineralization in vitro and in vivo [15–17]. These factors have motivated the development of 
various zinc-tricalcium phosphate materials, which have shown to be effective in treating bone-related 
ailments and traumas [18–21]. However, these materials currently lack the interconnected porous 
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network features of natural biomaterials and the synthesis of Zn-TCP requires high temperature 
sintering around 800–1000 °C [18]. With these in mind, this study is aimed to develop an alternative 
Zn-TCP material capable of improving the repairs of bone defects.  
2. Results and Discussion 
2.1. Physico-Chemical Characterization of Zn-TCP 
One of our key aims is to synthesize Zn-TCP using foraminifera macrospheres as a precursor 
material and evaluating the biological and bone healing response in a rat tibial defect. The production 
of Zn-TCP is based on hydrothermal conversion in which the carbonate component is replaced with 
phosphate ions while preserving the architectural structure of the material that can be potentially 
beneficial in bone regeneration. Our data shows Zn-TCP can be produced by hydrothermal conversion 
where zinc is substituted for calcium ions and this can be achieved at relatively low temperature  
(220 °C) compared with sintering. 
2.1.1. X-Ray Powder Diffraction (XRD) Analysis 
The replacement of carbonate ions with phosphate was verified crystallographically by XRD 
(Figure 1), which showed peak patterns matching tricalcium phosphate. It can be seen that the peaks of 
Zn-TCP does not differ much from that of tricalcium phosphate as the amount of zinc incorporated is 
at relatively low concentration (~5%).  
Figure 1. XRD peak patterns matched foraminifera calcareous (aragonite) material and 
hydrothermally synthesized zinc tricalcium phosphate (Zn-TCP) from JCPDS database.  
 
2.1.2. Quantitative Measurement of Ionic Composition of Samples 
Just like with the use of any pharmaceutical compounds, the therapeutic efficacy of zinc-related 
materials is highly dependent on the concentration. Supporting studies have shown that the most ideal 
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and optimal concentration is around the 5% range where excess amounts can induce inflammatory side 
effects [21]. The key chemical compositions of the materials (foraminifera, β-TCP and Zn-TCP) was 
quantified by mass spectroscopy and presented in Table 1. From the table, it can be seen that 
phosphate ions were successfully introduced into the material following hydrothermal conversion and 
calcium concentration was retained at similar levels. Quantitative measurements by mass spectroscopy 
showed the zinc concentration of the synthesized Zn-TCP is approximately 6%, which is within the 
therapeutic range.  
Table 1. Ionic composition of samples. 
Materials Calcium (mg/g) Phosphate (mg/g) Zinc (mg/g) 
Foraminifera 0.043 ± 0.0001 0 0 
β-TCP 0.045 ± 0.0002 0.0041 ± 0.0001 0 
ZnTCP 0.05 ± 0.0001 0.0046 ± 0.0001 0.0003 ± 0.00001 
2.1.3. Morphological Observation by Scanning Electron Microscopy (SEM) 
The rationale for using foraminifera precursor materials is due to the unique uniform and 
interconnected pores that the material naturally developed. By using hydrothermal conversion, these 
traits can be preserved during the transformation process. SEM micrographs presented in Figure 2 
reveals a naturally spherical/star shaped material, which upon closer examination, shows the 
uniformity of the pore (~2 μm in diameter) distribution throughout the surface of the sample.  
Figure 2. (a) Foraminifera carbonate material showing unique spherical structure and 
surface distribution of uniform pores; (b) Zn-TCP material showing preservation of the 
original structure and deposits of zinc ions on the surface structure. 
 
This could essentially allow for increase cell infiltration to regenerate bone and the development of 
crucial blood vessels allowing improved blood flow, supplying the area with essential nutrients. 
Previous studies by micro-computed tomography have shown that these materials are internally 
interconnected through the surface pores to a central hub [4]. Moreover, these pores are preserved 
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during the synthesis process and from Figure 2b additional deposits of zinc as determined by energy 
dispersive spectroscopy (EDS) can be seen scattered across the surface. This can potentially add to the 
therapeutic value of the material.  
2.2. Radiological and Histological Assessment of Bone Regeneration  
Zn-TCPs were implanted in a rat tibial defect model for eight weeks to evaluate the material’s bone 
healing properties. Zn-TCP samples were compared with empty control and β-TCP as a benchmark to 
determine the effectiveness of zinc in the bone healing process. The bone mineral density (BMD) 
(Figure 3a) and the bone mineral content (BMC) (Figure 3b) were calculated based on X-ray 
measurements and summarized in Figure 3. It should be noted that the BMD and BMC values took 
into account the presence of the sample material and that these were included in the results. The BMC 
values includes both cortical and trabecular bone amount.  
Figure 3. (a) Bone material density (BMD) values showing control and β-TCP group 
maintaining similar levels while Zn-TCP group showed statistical increase after eight 
weeks; (b) bone material content (BMC) which reflect on the new bone formed showed no 
significant growth in control group while β-TCP saw statistical growth after eight weeks. It 
was observed that Zn-TCP group showed a faster statistical bone growth after four weeks 
compared with control and β-TCP. Asterisk sign in Figure 3(a) and (b) represent p < 0.05, 
which was considered statistically significant. 
  
The BMD of the samples did not show any significant differences until eight weeks where Zn-TCP 
reached a statistically higher level compared with empty control and β-TCP. The complementing BMC 
data showed that Zn-TCP achieved a statistically higher level of bone mineral formation at four weeks 
compared with the control groups. This trend was also observed at eight weeks but with both β-TCP 
and Zn-TCP showing similar bone mineral levels compared with the significantly lower BMC of the 
empty control group. This result is in agreement with our hypothesis that β-TCP would have some 
degree of stimulatory action on bone formation as calcium and phosphate ions are released as the 
material degrades, thereby supplementing the defect area. Zn-TCP group was able to achieve a 
statistically higher bone mineral level as early as four weeks and was the only experimental group to 
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show a significant increase in BMD levels. This indicates that Zn-TCP was able to stimulate faster 
bone mineral formation through the actions of the released zinc ions. While in vitro studies have 
shown zinc to act on osteoblasts and osteoclasts, the exact mechanism of these effects is still poorly 
understood. It was shown that zinc could increase the osteogenic effect by increasing the osteoblast 
cell proliferation and stimulating alkaline phosphatase activity and collagen synthesis during the 
proliferation and differentiation phase [22]. 
2.2.1. Computed Tomography (CT) Imaging of Bone Regeneration 
The restoration of bone at the defect was observed using X-ray CT scans detailing the progressive 
bone regeneration illustrated in Figure 4. The control group showed that the majority of the cortical 
bone was restored at eight weeks but minimal trabecular bone can be seen within the marrow cavity. 
The β-TCP group showed at two weeks a thin layer of cortical bone developing at the defect and the 
progressive restoration of trabecular bone up to eight weeks. The image showed Zn-TCP to completely 
restore the cortical bone at the defect at four weeks and thickening of the bone can be seen at eight 
weeks. In addition, it can be seen that the restoration of the trabecular bone in the Zn-TCP group was 
more mature and dense compared with β-TCP. These results are in agreement with the BMD and BMC 
data results showed previously.  
Figure 4. CT images corresponding to the empty control (top), β-TCP (middle) and Zn-TCP 
(bottom) showing the progressive restoration of cortical and trabecular bone over eight 
weeks at the defect. Zn-TCP showed complete cortical bone restoration at four weeks and 
continuous growth of trabecular bone. The sample materials are highlighted in red.  
 
2.2.2. Histological Assessment of Defect Site 
Figure 5 show histological HE-stained slices of (a) control, (b) β-TCP and (c) Zn-TCP with 
corresponding images shown at higher magnification. From the images it can be seen that both β-TCP 
and Zn-TCP were able to stimulate regeneration of new bone closing the defect, but were also 
regenerating cancellous bone. The empty control group only showed a very small amount of 
regenerated cancellous bone. The higher magnification images reveal the internal porous chambers of 
the β-TCP and Zn-TCP material showing new bone in-growth penetrating these porous networks. The 
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ability of the biomaterial to promote bone infiltration is crucial in generating good integration between 
the material and its surrounding environment. Upon closer observation of these porous chambers, the 
presence of blood vessels with the newly formed bone could be observed suggesting good blood flow 
allowing the required nutrients to aid in the regeneration process.  
Figure 5. HE-stained bone: (a) Control group with bone site regenerated, but, at higher 
magnification showed minimal cancellous bone growth; (b) β-TCP reveals the internal 
structure of the material with porous chambers penetrated by new formed bone and 
presence of blood vessels; (c) Zn-TCP sample shows similar results to β-TCP, with new bone 
formed within the porous chamber of the material showing good bone-material integration. 
 
These results may have significant implication in bone fracture repair and it is hoped this can 
provide the background for future studies in the development of more bioactive biomaterials for bone 
fracture repair. Current and future studies will examine the activity of Zn-TCP in larger animal models 
and in critical-sized defect models.  
3. Experimental Section  
3.1. Production, Synthesis and Evaluation of Zn-TCP  
The foraminifera carbonate samples were commercially acquired (Okinawa Business Support 
Okinawa, Okinawa, Japan) and cleaned for 25 min in sodium hypocholorite to remove any 
contaminants. The carbonate samples were first hydrothermally converted to tricalcium phosphate 
using aqueous diammonium hydrogen-phosphate (Wako Chemical Co., Tokyo, Japan) with Ca/P 
molar ratio adjusted to 1.5, then heating the specimen in a high pressure vessel to 220 °C for 48 h. The 
aqueous solution was replaced with aqueous zinc nitrate hexahydrate solution (Wako Chemical Co., 
Tokyo, Japan) with Ca/Zn ratio adjusted to 19/2 to produce 5% Zn-TCP samples. The samples 
underwent another hydrothermal treatment again by heating to 220 °C for 48 h to produce Zn-TCP. 
The crystallographic characterization was performed by powder X-ray diffraction analysis  
(RINT-Ultima-III, Rigaku Co., Tokyo, Japan; CuKα radiation, 40 kV, 40 mA) with peak patterns 
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matched with JCPDS database. The surface morphological structures of all the specimens were 
observed using a scanning electron microscope (JEOL JSM-7600F, Field Emission SEM, 10 kV, 
Tokyo, Japan). The in vitro dissolution kinetic studies were evaluated in a previously published  
study [1]. The ionic compositions of the samples were quantified by inductively coupled plasma-mass 
spectroscopy (ICP-MS) using an Agilent Technologies 7500 ce series ICP-MS (Agilent, Sydney, 
Australia). Sample introduction was made via a micromist concentric nebuliser (Glass expansion) and 
a Scott type double pass spray chamber cooled to 2 °C. The sample solution and the spray chamber 
waste were carried with the aid of a peristaltic pump. The ICP operating parameters and the lens 
conditions were selected to maximise the sensitivity of a mixture of 1% HNO3, 1% HCl solution 
containing 1 ng/mL of Li, Co, Y, Ce and Tl. Helium was added into the octopole reaction cell to 
reduce interference. Calibration curves were constructed and the results analysed using Agilent 
Technologies Masshunter software. Approximately 0.005 g of sample was digested with 0.25 mL of 
1%HNO3. Once the digestion was completed, the sample volume was made up to 5 mL with water. 
The samples underwent a further 1:100 dilution with a 1% nitric acid solution before ICP-MS analysis. 
Samples were diluted further in nitric acid as required. 
3.2. Animal Maintenance and Surgical Procedures 
Animal care and studies were in accordance to the guidelines and approval from the Animal Ethics 
Committee at Musashino University, Japan. Thirty, 15-week-old Wistar male rats were randomly and 
equally divided into three groups: (1) Control (Ctrl); (2) beta-tricalcium phosphate (β-TCP); and  
(3) zinc-tricalcium phosphate (Zn-TCP). The animals were monitored on a daily basis for signs of 
inflammation during the early stages of recovery and their weights were recorded on a weekly basis to 
ensure normal growth of the animal. The rats were initially anesthetized intramuscularly using a 
combination of ketamine (40 mg/kg) and xylazine (4 mg/kg). The area around the incision site was 
shaved and disinfected with alcohol and an incision of approximately 1 cm long was made to expose 
the tibia where a 2 mm in diameter and 3 mm in depth cylindrical defect was made using a fissure bur 
under constant saline irrigation. Defects were either left empty (control group) or filled with two  
β-TCP and ZnTCP samples. The soft tissue was closed in two layers with absorbable sutures and the 
wound region was disinfected again. The animals were sacrificed after eight weeks and radiologic and 
histologic analyses were used to assess total bone mineral content and bone mineral density. 
3.3. Radiological and Histological Assessment of Defect  
Radiological assessment of the defect site was made by scanning every two weeks using X-ray 
computed tomography (X-Ray CT) (Latheta 200, Aloka, Tokyo, Japan) and evaluating changes in 
bone mineral density and bone mineral content by software (Latheta, Aloka, Tokyo, Japan). At  
eight weeks, the animals were sacrificed and the tibia was excised and fixed in 10% formalin (Wako 
Chemicals, Tokyo, Japan). The fixed samples were subsequently decalcified in 5% formic acid (Wako 
Chemicals, Tokyo, Japan) for four weeks. After decalcification, the samples were dehydrated in 
ascending grades of ethanol and embedded in paraffin where 5 µm thick coronal sections of the central 
area at the defect site was cut and prepared for staining with hematoxylin and eosin (H&E).  
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3.4. Statistical Analysis 
Statistical analysis was performed by using SPSS Ver 11.5 for Windows. ANOVA with Scheffe test 
was used for comparing the significance amongst the groups. P values of less than 0.05 were 
considered to be statistically significant. 
4. Conclusions  
Based on these findings, biomimetic Zn-TCP showed improved restoration of bone in a rat tibial 
defect model with β-TCP and empty control group. The present study showed that Zn-TCP derived 
from foraminifera carbonate precursor material could stimulate accelerated bone formation compared 
with β-TCP and empty control when implanted in rat tibial defects. It was also shown that newly 
formed bone infiltrated the porous chambers of the material and the presence of blood vessels was 
observed within these chambers.  
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